• MASTER-2 (Relapsing MS Trial)

Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03933202

  

  • GEMINI2 – EFC 16034

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis – To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04410991?titles=GEMINI2

 

  • PERSEUS – EFC 16035

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) – To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04458051?titles=PERSEUS

 

  • ASPIRE

The study is being conducted to determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).  A secondary Aim is to determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale. ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03907046